Latest Whitepapers

A scalable and robust solution for all stages of the gene therapy workflow to meet regulatory standards is essential, however, as the field is more recent, liquid media is the common format even though it can be more expensive and have a shorter shelf life.

Active cell therapy drugs represent the latest in cancer treatment. Of these, chimeric antigen receptor (CAR) cell modalities are considered the most successful.

Solid form informatics (SFI) provides a knowledge-based approach to improve the effectiveness and quality of early-phase drug discovery research, as well as a rational approach to risk assessment.

Chemical supply chain issues can have real, quantifiable impacts on biomanufacturers. While the efficient management of storage and inventory can help to reduce risk, it can also prove resource intensive and increase the total cost of ownership.

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.

Innovation is key for any biopharmaceutical and biotechnology company. Whilst the demand for infectious disease prevention continues to grow, so does the pressure on these companies to deliver innovative solutions.

In this whitepaper, learn how the innovative features of the cobas t 711 coagulation analyzer address the need for greater efficiency, improved workflow and reliable results, potentially allowing laboratory staff to gain more time to focus on validation and clinical interpretation.

Process development teams need detailed information, via a platform that delivers short gradients to allow the required sample throughput to detect HCPs in a low sub-ppm range.

Flow cytometry is an important part of the drug discovery workflow. From screening antibodies to small molecules, combining tests for various analytes in a single panel not only reduces the necessary sample volume but also collects more information in less time, accelerating the drug discovery process.

The EU GMP Annex 1 provides specific guidance on the manufacture of sterile medicinal products. Though it is a European guide for manufacturing, EU GMP Annex 1’s impact is global. So how does the latest revision affect you?